Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
enGene Therapeutics Inc banner
E

enGene Therapeutics Inc
NASDAQ:ENGN

Watchlist Manager
enGene Therapeutics Inc
NASDAQ:ENGN
Watchlist
Price: 1.91 USD -2.55% Market Closed
Market Cap: $128m
Write Note Create Alert Ask AI

Bankruptcy Probability

enGene Therapeutics Inc's probability of bankruptcy is 2.8%, pointing to a small but noticeable default risk. The solvency score is 55/100 — a warning sign of potential financial weakness.

We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.

Moderate
Probability of Bankruptcy

Financial Position

Cash & Short-Term Investments
+
3Y
+608%
5Y
-
10Y
-
Long-Term Investments
+
3Y
-
5Y
-
10Y
-
Debt
+
3Y
-62%
5Y
-
10Y
-

Solvency Ratios

Solvency Ratios Comparison
enGene Therapeutics Inc Competitors

Country Company Market Cap D/E D/A Interest
Coverage 		Altman
Z-Score 		Quick
Ratio 		Current
Ratio 		Cash
Ratio
CA
enGene Therapeutics Inc
NASDAQ:ENGN
131.3m USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
AbbVie Inc
NYSE:ABBV
467.1B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Amgen Inc
NASDAQ:AMGN
224.3B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Gilead Sciences, Inc
NASDAQ:GILD
187.3B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
133.3B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.5B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Moderna Inc
NASDAQ:MRNA
79.4B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
NL
argenx SE
XBRU:ARGX
52.8B EUR
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
AU
CSL Ltd
ASX:CSL
84.7B AUD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Natera Inc
NASDAQ:NTRA
59.2B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Revolution Medicines Inc
NASDAQ:RVMD
43.9B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
No Stocks Found

Continue ENGN Research

Summary
ENGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
ENGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ENGN stock valuation using valuation multiples.
Wall St Estimates
ENGN price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ENGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Is enGene Therapeutics Inc at risk of bankruptcy?

enGene Therapeutics Inc's probability of bankruptcy is 2.8%, pointing to a small but noticeable default risk.

The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.

How much debt does enGene Therapeutics Inc have?

As of the latest report, enGene Therapeutics Inc has total debt of 25.2m USD. This includes both short-term (0 USD) and long-term (25.2m USD) debt.

You can find a full breakdown on its Balance Sheet.

Back to Top
ALPHA SPREAD
Follow us
Join 359,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.